Related Experiment Video
Updated: Jan 18, 2026
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus
Veronique de Jager1, Laurynas Mockeliunas2, Huifang You2
1TASK, Cape Town, South Africa.
Background:
In vitro, meropenem is shown to restore the activity of rifampicin in rifampicin-resistant Mycobacterium tuberculosis strains. This phase 2a trial aimed to determine if addition of rifampicin increases the early bactericidal activity (EBA) of meropenem plus amoxicillin/clavulanate in patients with rifampicin-resistant tuberculosis (RR-TB).
Methods:
Individuals with RR-TB were randomized to either 2 g meropenem infusion 3 times daily plus amoxicillin/clavulanate 500 mg/125 mg orally 3 times daily with 20 mg/kg rifampicin orally once daily (M-AC-R arm) or the same treatment without rifampicin (M-AC). Sputum samples were collected at baseline and throughout the 14-day treatment. Colony-forming unit (CFU) and time-to-positivity (TTP) data were analyzed using nonlinear mixed-effects modeling. Plasma samples at day 13 were used to derive rifampicin and meropenem pharmacokinetic parameters using noncompartmental analysis. Rifampicin minimum inhibitory concentrations (MICs) were determined from baseline sputum isolates with and without meropenem.
Results:
Of the 52 participants enrolled, 38 participants completed the trial. The majority (67%) were male, and the median age was 37 years. The median (95% prediction interval) predicted 14-day EBA in CFU was 1.33 (-0.15 to 3.64) and 1.20 (0.05-2.66) log10 CFU/mL, and TTP increased by 0.220 (0.098-0.551) and 0.216 (0.126-0.505) log10 hours for the M-AC-R and M-AC arms, respectively. No statistically significant difference was found between the 2 arms. Meropenem pharmacokinetics were similar in both arms, and rifampicin MICs were not meaningfully reduced by meropenem.
Conclusions:
Adding rifampicin to meropenem plus amoxicillin/clavulanate did not enhance short-term antibacterial activity in patients with RR-TB.
More Related Videos
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:20Sputum Studies II: Culture and Sensitivity
Sputum culture and sensitivity is a medical procedure used to diagnose bacterial infections in the respiratory tract and select the most appropriate antibiotics for treatment. This process involves analyzing sputum samples of thick and opaque secretions produced in the lungs and airways. These samples are collected from patients and then sent to the laboratory for analysis.
The test can identify various pathogens responsible for respiratory infections, including Streptococcus,...
01:31Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...